Physician profile
Carmen B Meier
NPI 1306046107
$4,940.54
in general payments reported to CMS, 2019-2025
24 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $165 · 2021: $647 · 2022: $934 · 2023: $1,352 · 2024: $651 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233 · Travel and Lodging: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.28 |
| Travel and Lodging | $696.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,737.99 | 2022-2025 | Interstim |
| Abbvie INC. | $1,298.13 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $312.42 | 2019-2022 | |
| Madrigal Pharmaceuticals | $298.80 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $171.30 | 2023-2024 | Dupixent |
| Redhill Biopharma INC. | $146.27 | 2020-2021 | |
| Cook Medical LLC | $133.69 | 2022 | |
| Janssen Biotech, INC. | $131.86 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.53 | 2019-2023 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $110.93 | 2020-2024 | |
| Janssen Scientific Affairs, LLC | $108.67 | 2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $68.85 | 2021-2022 | |
| Lilly USA, LLC | $64.08 | 2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $63.64 | 2022-2023 | Rebyota |
| Boston Scientific Corporation | $24.38 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24.00 | 2023 | |
| Dexcom, INC. | $21.88 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $20.38 | 2023 | |
| Medtronic USA, INC. | $19.61 | 2020 | |
| Novo Nordisk INC | $15.60 | 2025 | Wegovy |
| Olympus America INC. | $14.34 | 2023 | Evis Exera III Video System Center |
| Braintree Laboratories, INC. | $14.33 | 2021 | |
| Daiichi Sankyo INC. | $13.59 | 2022 | |
| Organon LLC | $5.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Meier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.